(Q36761416)

16 August 2017

1 reference

title

Disialoganglioside directed immunotherapy of neuroblastoma (English)

1 reference

16 August 2017

1 reference

2

Nai-Kong V Cheung

1 reference

16 August 2017

Shakeel Modak

1

1 reference

16 August 2017

publication date

1 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

25

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

67-77

1 reference

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Vaccine therapies for pediatric malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Genomic organization and chromosomal assignment of the human beta1, 4-N-acetylgalactosaminyltransferase gene. Identification of multiple transcription units

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Early Molecular Response of Marrow Disease to Biologic Therapy Is Highly Prognostic in Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Detecting minimal residual disease in neuroblastoma patients-the present state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Monoclonal antibody-based therapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

FCGR2APolymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900601130763

10.1080/07357900601130763

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference